vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and CarParts.com, Inc. (PRTS). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $120.4M, roughly 1.5× CarParts.com, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -9.6%, a 11.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -9.8%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -8.6%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Genuine Parts Company (GPC) is an American automotive and industrial parts distributor based in Atlanta, Georgia. Established by brothers Carlyle and Malcolm Fraser in 1928, the company has approximately 60,000 employees. In addition to the United States, GPC has operated in Australasia, Belgium, Canada, France, Germany, Mexico, the Netherlands, Poland, and the United Kingdom. GPC's subsidiaries include industrial parts distributor Motion as well as NAPA Auto Parts, which primarily sells part...
PCRX vs PRTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $120.4M |
| Net Profit | $2.9M | $-11.6M |
| Gross Margin | — | 33.2% |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | -9.6% |
| Revenue YoY | 5.0% | -9.8% |
| Net Profit YoY | — | 25.0% |
| EPS (diluted) | $0.07 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $120.4M | ||
| Q3 25 | $179.5M | $127.8M | ||
| Q2 25 | $181.1M | $151.9M | ||
| Q1 25 | $168.9M | $147.4M | ||
| Q4 24 | $187.3M | $133.5M | ||
| Q3 24 | $168.6M | $144.8M | ||
| Q2 24 | $178.0M | $144.3M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-11.6M | ||
| Q3 25 | $5.4M | $-10.9M | ||
| Q2 25 | $-4.8M | $-12.7M | ||
| Q1 25 | $4.8M | $-15.3M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $-143.5M | $-10.0M | ||
| Q2 24 | $18.9M | $-8.7M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 33.2% | ||
| Q3 25 | 80.9% | 33.1% | ||
| Q2 25 | 77.4% | 32.8% | ||
| Q1 25 | 79.7% | 32.1% | ||
| Q4 24 | 78.7% | 32.5% | ||
| Q3 24 | 76.9% | 35.2% | ||
| Q2 24 | 75.1% | 33.5% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | -7.9% | ||
| Q2 25 | 4.7% | -8.2% | ||
| Q1 25 | 1.2% | -10.3% | ||
| Q4 24 | 13.2% | -11.6% | ||
| Q3 24 | -82.8% | -6.9% | ||
| Q2 24 | 15.9% | -6.0% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -9.6% | ||
| Q3 25 | 3.0% | -8.5% | ||
| Q2 25 | -2.7% | -8.4% | ||
| Q1 25 | 2.8% | -10.4% | ||
| Q4 24 | — | -11.5% | ||
| Q3 24 | -85.1% | -6.9% | ||
| Q2 24 | 10.6% | -6.0% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.82 | ||
| Q3 25 | $0.12 | $-0.19 | ||
| Q2 25 | $-0.11 | $-0.23 | ||
| Q1 25 | $0.10 | $-0.27 | ||
| Q4 24 | $0.38 | $-0.28 | ||
| Q3 24 | $-3.11 | $-0.17 | ||
| Q2 24 | $0.39 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $25.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $53.5M |
| Total Assets | $1.2B | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $25.8M | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $53.5M | ||
| Q3 25 | $727.2M | $64.2M | ||
| Q2 25 | $757.8M | $62.4M | ||
| Q1 25 | $798.5M | $72.8M | ||
| Q4 24 | $778.3M | $85.2M | ||
| Q3 24 | $749.6M | $97.2M | ||
| Q2 24 | $879.3M | $103.9M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $184.9M | ||
| Q3 25 | $1.3B | $200.3M | ||
| Q2 25 | $1.5B | $189.6M | ||
| Q1 25 | $1.6B | $216.5M | ||
| Q4 24 | $1.6B | $210.6M | ||
| Q3 24 | $1.5B | $227.6M | ||
| Q2 24 | $1.6B | $238.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PRTS
Segment breakdown not available.
